## Edgar Filing: Lyons C Neil - Form 4

Form 4									
May 15, 2013								OMB A	PPROVAL
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).	StateMent of changesStateMent of CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESExpires:January 3 200stimated average burden hours per response200Statement of changesSector 16(a) of the Securities Exchange Act of 1934, 30(h) of the Investment Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940Expires:200Section 17(a) of the Public Utility Holding Company Act of 1940Section 17(a)Section 17(a)Section 17(a)								urs per
(Print or Type Respon	nses)								
1. Name and Addres Lyons C Neil	2. Issuer Name <b>and</b> Ticker or Trading Symbol CLEVELAND BIOLABS INC [CBLI]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) ( C/O CLEVELAN INC., 73 HIGH S	3. Date of Earliest Transaction (Month/Day/Year) 05/13/2013			Director 10% Owner X Officer (give title Other (specify below) Chief Financial Officer					
Filed(Month/Day/Year) Applicable Line)   _X_ Form filed by C						int/Group Filing(Check Dne Reporting Person Iore than One Reporting			
(City) (	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities /	Acquired, Disposed	of. or Beneficia	llv Owned
	ansaction Date th/Day/Year)	Execution any	ed Date, if	3. Transacti Code (Instr. 8)	4. Securi onAcquired Disposed (Instr. 3, Amount	ties l (A) or l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect
Reminder: Report on	a separate line	e for each cl	ass of sec	urities ben	eficially ow	ned directly	or indirectly.		
					Perso infor requi	ons who re nation con red to resp ays a curre	spond to the colle tained in this form ond unless the for ently valid OMB co	i are not rm	SEC 1474 (9-02)
	Tab					sposed of, or convertible	r Beneficially Owned securities)	I	

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDerivative	Expiration Date	Underlying Securities

## Edgar Filing: Lyons C Neil - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed ( (D) (Instr. 3, 4, and 5)	(Month/Day	/Year)	(Instr. 3 and	4)
				Code V	(A) (I	) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 1.54	05/13/2013		A	77,131	<u>(1)</u>	05/13/2023	Common Stock	77,131

## **Reporting Owners**

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Lyons C Neil C/O CLEVELAND BIOLABS, INC. 73 HIGH STREET BUFFALO, NY 14203			Chief Financial Office	r
Signatures				
/s/ Leah Brownlee, Attorney-in-fact for Lyons	r C. Neil	(	05/15/2013	
**Signature of Reporting Person			Date	
Explanation of Respo	nses:			

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option becomes exercisable on the date on which the Company's Common Stock had an average closing price of \$5.00 or greater over a period of five continuous trading days.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.